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rameters, showing correlation with the clinical response
achieved. There were significant changes in major compo-
nents of QLQ-C30 in pts who achieved clinical response.
PCN6
CAN ICD-9 CODES BE USED AS A PROXY FOR 
DISEASE STAGING IN ECONOMIC 
EVALUATIONS?
Thomas SK, Brooks SE, Mullins CD
University of Maryland, Baltimore, MD, USA
Administrative health care databases are increasingly
used as a source of data for economic studies in cancer.
In order to adjust for disease severity, several investiga-
tors have utilized ICD-9 codes indicating metastases as a
proxy for cancer staging. OBJECTIVE: To determine the
validity of using ICD-9-CM codes indicating metastases
as a proxy to classify lung cancer patients by stage of dis-
ease. METHODS: This retrospective database analysis
used diagnosis codes to classify subjects to either local-
ized or advanced stage disease and then compared this
classification to the tumor registry staging, which was
considered as the “gold standard”. Study subjects in-
cluded all lung cancer patients treated at an academic in-
stitution during 1996–97 who were also members of a
large insurance company. Data was derived from inpa-
tient cancer-related claims linked with the institution’s
tumor registry data. Advanced stage disease (stages II to
IV) was defined by claims indicating lymph node involve-
ment or metastases (ICD-9 codes 196-199.1). The tumor
registry staging of the disease for these patients were clus-
tered into two groupings, stages 0–I (localized) and stages
II–IV (advanced). RESULTS: Tumor registry entries were
identified for 85.7% of patients. The crude concordance
between the claims and tumor registry classifications was
74.2% (Kappa coefficient  0.4848). The positive pre-
dictive value of identifying localized disease utilizing
ICD-9 coding was 57.6%,while the predictive value of a
negative test was 91%. The sensitivity and specificity for
dichotomized disease stage was 86.4% and 68.2% re-
spectively. CONCLUSIONS: For a population of lung
cancer patients in an academic institution, the use of
ICD-9 coding was associated with modest predictability
for disease staging. The use of ICD-9 coding as a proxy
for disease staging in economic evaluations should be ex-
ecuted with caution.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is one of the main treat-
ment options but its availability in the UK is limited in
comparison to other countries, is inconsistent across geo-
graphical regions, with many patients receiving only pal-
liative care. The present study reports results of an eco-
nomic evaluation of Gemzar (one of the newer agents
available) and best supportive care (BSC) relative to BSC
in the treatment of advanced NSCLC. BSC relates to all
forms of care which are non-curative in intent excluding
chemotherapy. METHODS: The study is undertaken
from the perspective of the UK NHS. Data were ex-
tracted from a comparative trial undertaken in the UK
(Anderson et al in 1997). Cost estimates are based on:
chemotherapy and associated infusion, hospitalisations,
health care professional visits, concomitant medications,
radiotherapy and terminal palliative care. Resource utili-
sation data from the clinical trial were combined with
unit-cost data from various UK sources. Costs are pre-
sented in 2000 price levels and the time horizon for their
estimation is one year; hence discounting was unneces-
sary. Treatment effectiveness is measured by progression-
free survival and tumour response. Extensive sensitivity
analysis was also performed. RESULTS: Total treatment
cost per patient in the Gemzar/BSC arm was estimated at
£5,502 and at £3,861 for the BSC arm, the difference at-
tributed mainly to the drug (Gemzar) and its administra-
tion costs. The intervention arm had lower radiotherapy/
concomitant medication costs, but this did not offset the
drug acquisition cost. Progression free life years and
overall tumour response rates were 0.789 and 18.5% in
the Gemzar/BSC arm and 0.474 and 0% in the BSC arm.
The incremental cost-per-progression-free-life-year gained
in Gemzar/BSC relative to BSC is £5,228 and the incre-
mental cost-per-tumour-response £8,873. Changes in the
key variables varied the above ratios between £3,000 and
£23,000. CONCLUSIONS: The economic evaluation
presented above shows that Gemzar/BSC is a cost-effec-
tive therapy for advanced NSCLC relative to BSC alone.
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OBJECTIVES: Pancreatic cancer is a significant and in-
creasing cause of morbidity and mortality in the UK.
Treatment with chemotherapy has shown to improve
symptoms and survival of patients. Gemzar is licenced
for treatment of pancreatic cancer in the UK. This study
reports on an economic evaluation of Gemzar relative to
5-FU, a commonly used regimen for advanced pancreatic
cancer patients in the UK. METHODS: The perspective
is that of the UK-NHS. Data were derived from a clinical
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trial (Burris et al in 1998). Total treatment costs esti-
mates are based on chemotherapy, infusions, hospitalisa-
tions, visits to health care professionals and concomitant
medications. Resource utilisation data, derived from the
trial, were combined with unit cost data from various UK
sources. The time horizon is 18 months and costs relate
to 2000. A 6% discounting rate was applied. Effective-
ness was measured by: survival, progression-free survival,
and % of clinical benefit responders Extensive sensitivity
analysis was performed to test the robustness of the re-
sults. RESULTS: Total treatment cost per patient on
Gemzar was estimated at £3,569 and on 5-FU at £1,262—
the difference attributed mainly to higher drug acquisi-
tion costs. Gemzar was associated with an incremental
gain of 0.188 life years, 0.116 progression-free-life-years
and 19% of patients could be classifed as clinical benefit
responders. As such, relative to 5-FU, the incremental
cost-per-clinical-benefit-responder with Gemzar is £12,172,
the incremental cost-per-life-year-gained is £12,206 and
the incremental cost-per-progression-free-life-year gained
is £19,888. Sensitivity analyses showed that the results
did not vary significantly with changes of the parameters.
When 5-FU is administered by continuous infusion, the
cost per patient increases to £1,900 and the incremental
cost-effectiveness of Gemzar is improved. CONCLU-
SIONS: This economic evaluation demonstrates that
Gemzar consists a cost-effective alternative to an existing
therapy that is commonly used in the UK for treatment of
pancreatic cancer. The incremental cost-effectiveness of
Gemzar compares favourably with that of other treat-
ments funded by the NHS.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is a main treatment op-
tion but its availability in the UK is limited in comparison
to other countries and is not consistent across geographi-
cal regions. The present study reports on two economic
evaluations of Gemzar/cisplatin relative to: paclitaxel/
cisplatin, paclitaxel/carboplatin, docetaxel/cisplatin (eval-
uation 1); and vinorelbine/cisplatin (evaluation 2). METH-
ODS: The perspective is that of the UK-NHS. Informa-
tion was derived from randomised clinical trials (Schiller
et al 2000 (evaluation 1), Comella et al 2000 (evaluation
2)). Total treatment costs include: chemotherapy and in-
fusion, hospitalisations, visits to health care profession-
als, and concomitant medications. Resource utilisation
information was combined with unit cost data from vari-
ous UK sources. Costs relate to 2000 and were adjusted
with the NHS inflation index if necessary. The time hori-
zon for the estimation of costs is one year; hence dis-
counting was unnecessary. Treatment effectiveness is
mainly measured by time to disease progression and
overall survival. RESULTS: In the first evaluation the
cost per patient in the Gemzar/cisplatin, paclitaxel/cis-
platin, paclitaxel/carboplatin, docetaxel/cisplatin arms was
£5,537, £9,043, £8,444, and £5,779 respectively. Thus,
the Gemzar/cisplatin achieves cost savings up to £3506,
which is driven by lower chemotherapy costs. Progres-
sion-free-life-years for each treatment arm, in the order
presented above, were 0.375, 0.292, 0.300 and 0.275 re-
spectively. Thus, the Gemzar/cisplatin combination dom-
inates the other three combinations. In evaluation 2, a
conservative approach was used whereby the survival
outcome was assumed to be equivalent between Gemzar/
cisplatin and vinorelbine/cisplatin arms. However, the
cost in the Gemzar/cisplatin arm was £4,476 and in the
vinorelbine/cisplatin arm £5,047. Despite significant
changes to important parameters Gemzar with cisplatin
maintains dominance or achieves very low positive incre-
mental cost-effectiveness ratios, the maximum of which is
£1,200. CONCLUSIONS: Gemzar/cisplatin is less expen-
sive and equally or more effective than the other alterna-
tive regiments. Thus, on cost-effectiveness grounds, it
should be encouraged in the treatment of NSCLC pa-
tients in the UK.
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PROSTATE CANCER
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BACKGROUND: Prostate cancer is the most common
type of malignancy found in US male population and the
second leading cause of cancer fatality in men. PSA
screening is a common test in prostate cancer diagnosis.
This research investigates its cost-effectiveness. METH-
ODS: A cost-effectiveness model is constructed following
a cohort of patients aged 60 to 75 taken from a general
US population. Clinical outcomes, costs, and transition
state probabilities were derived from medical literature
and used to construct a Markov state probability model.
The analysis takes a societal perspective and all costs
were converted to 2000 dollars. Discount rate in base
case was 3%. The parameters in the base-case were as-
sessed for robustness using one-way sensitivity analysis.
RESULTS: We found that a screening program with
annual PSA testing starting at age 60 would result in
cost-effectiveness ratios of $8000 per QALY. One-way
sensitivity testing found the results to be very stable.
Threshold analysis revealed that screening ceased to be
cost-effective (CE ratio $50,000/QALY) only when
costs for procedures such as prostate surgery approached
$500,000 or prostate cancer was detected at high levels
(80% true positives in first year of testing, up from cur-
